The Effect of an Edible Algal Extract (Ulva Lactuca) on the Component of Depression in Healthy Volunteers With Anhedonia

Anhedonia in Healthy Volunteers Clinical Trial

Official title:

Essai Clinique randomisé en Double Aveugle Contre Placebo de l'évaluation de l'Effet d'un Extrait d'Algues Comestibles (Ulva Lactuca) Chez Des Volontaires Sains présentant Une anhédonie associée à Une Baisse de Moral

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03545399
• Other study ID #: C1365
• Status: Completed
• Phase: N/A
• Start date: June 29, 2015
• Est. completion date: May 31, 2016

Study information

• Verified date: May 2018
• Source: CEN Biotech
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The effects of the seaweed extract were evaluated on the animal model equivalent of depression compared with a control group treated with the carrier (spring water) and a reference group treated with Imipramine and showed significative effect. This clinical trial was intended to confirm in humans the potential efficacy identified in animals. The primary objective was to compare against a placebo the effect of Ulva L.L extract in healthy volunteers whose anhedonia was characterized by a component of depression.

Description:

The trial comprised three visits: a medical enrollment visit on D0, an intermediate visit on D28 and a final visit on D84. A psychologist made a telephone call after 7 days to check there was no sudden change in the subject's depressive state. During the visits, the subject was examined by a doctor and the psychometric tests were administered by a psychologist. Outside the visits, the subject was monitored by a self-reporting questionnaire in the manner described below.

After obtaining informed written consent and validating the inclusion and exclusion criteria, notably the absence of MDE as per DSM V, the investigator enrolled the subject in the trial. The physician described the subject's demographic and general clinical characteristics, the main medical and surgical history and any current treatment if those pathologies were still present, and any previous antidepressant, anxiolytic or neuroleptic treatments. The doctor asked the subject to complete the SHAPS and QIDS -SR questionnaires and item 7 of the HAM-D. The doctor then handed the subject self-evaluation questionnaires explaining how to complete them and the dates at which they were to be completed. The physician gave the patient a batch of the placebo or a batch of Ulva lactuca as per the randomization. The doctor told the subject a psychologist would be in touch after one week by telephone to check no DSM V severity criterion had arisen.

The investigating doctor saw the subject again at the four-week intermediate visit and at the final visit at the end of the 12th week of follow-up. The doctor collected the self-questionnaires at these visits and the same items as at the enrollment visit were recorded by the physician for describing how the items had evolved and notably the SHAP scale score, the QIDS-SR and item 7 of the HAM-D. In addition, the physician recorded the subject's satisfaction with the treatment evaluated on the PGII (Patient Global Improvement Impression), reported any undesirable affects and gave his/her own opinion on the efficacy of treatment using the Clinical Global Improvement Impression (CGII).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: May 31, 2016
• Est. primary completion date: May 31, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Men or women aged between 18 and 65 years

• Presenting a anhedonia with a score =5 on the SHAPS Scale

• Declaring feeling low for at least 4 weeks characterised by a component of depression evaluated on the QIDS-SR

• Being able to apprehend and fill in the evaluation scales

Exclusion Criteria:

• Subject with a major depressive episode as per the DSM V scale, with a HAM D > 8, already on anxiolytic, antidepressor, neuroleptic or any other medicinal treatment liable to influence mood (e.g. benzodiazepines) in the last 30 days or using illegal psychotropic substances, or a with daily alcohol intake of more than three glasses of wine

• Presenting a psychiatric disorder or in state of post-traumatic stress or having had an electroconvulsive therapy in the last 6 months

• Female subject pregnant or breast-feeding or of childbearing age and not using effective means of contraception

• subject suffering from an allergy or intolerance to seafood products (fish, shellfish and seaweed)

Related Conditions & MeSH terms

• Anhedonia
• Anhedonia in Healthy Volunteers

Intervention

Dietary Supplement:
• Ulva Lactuca
The dose was taken with a glass of water during the evening meal once daily
• Placebo
The dose was taken with a glass of water during the evening meal once daily

Locations

Country	Name	City	State
n/a

Sponsors (4)

Lead Sponsor	Collaborator
CEN Biotech	Amadeite SAS, Biovet Conseil, CEN Nutriment

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evolution of anhedonia in healthy subjects	The evolution of anhedonia in healthy subjects whose anhedonia was characterized by a component of depression was measured by the Snaith-Hamilton Pleasure Scale (SHAPS).The SHAPS questionnaire is composed of 14 questions, the total score of the SHAPS varies between 0 and 14. Severe anhedonia will be observed if the SHAPS score is strictly greater than 5.	84 days
Secondary	Evolution of the subject's mood	Evolution of the mood of subjects measured by the Brief Mood Introspection Scale (BMIS).Each "positive" item (Dynamic, Happy, Compassionate, Content, Energetic, Quiet, Affectionate and Vivid) is rated from 1 "Not at all" to 4 "Absolutely". Each item "negative" (Sad, Tired, Melancholic, Excited, Exhausted, Grumpy, Nervous and Annoyed) is inversely rated from 1 "quite" to 4 "not at all". The BMIS questionnaire is composed of 16 questions, and will be calculated by adding the answers of these 16 items. The BMIS score varies between 16 and 64.	84 days
Secondary	The effect on work and other activities	The effect on work and other activities according to item 7 of the Hamilton Rating Scale for Depression (HAM-D).The HAM-D is a scale for depression composed of 17 questions and varies between 0 and 58.; The HAM-D score will also be classified into 5 classes according to the following model: 0-7 None; 8-13 Light; 14-18 Moderate; 19-22 Severe; > 23 Very severe	84 days
Secondary	Evolution of the components of depression	Evolution of the components of depression is measured by the Quick Inventory of Depressive Symptomatology -Self-Report (QIDS-SR).QIDS-SR questionnaire is composed of 16 questions. Each answer is scored from 0 to 3. The symptomatology is more important with a higher score. The total score fluctuates between 0 and 27.; The QIDS score will also be classified into 5 classes according to the following model: 0-5 None; 6-10 Lightweight; 11-15 Moderate; 16-20 Severe; > 20 Very severe	84 days
Secondary	Evaluation of subject's satisfaction	Subject's satisfaction with the treatment was evaluated by the Patient Global Improvement Impression (PGII)	84 days
Secondary	Evaluation of product's tolerance	The evaluation of product's tolerance for the whole period of the trial is done by the reporting of Serious Adverse Event if any	84 days
Secondary	Evaluation of the investigator's opinion	Evaluation of the investigator's opinion is measured by the Clinical Global Improvement Impression (CGII)	84 days